EIC Accelerator funds VBL as it approaches the final enrollment phase of its key product candidate, ofra-vec (VB-111), for ovarian cancer. The CEO perceives this investment as acknowledgment of the potential ofra-vec offers to patients and the current critical need in ovarian cancer therapies.